Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
arenapharm.com

See what CB Insights has to offer

Founded Year

1997

Stage

Acq - P2P | Acquired

Total Raised

$37.83M

Valuation

$0000 

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory diseases, and metabolic diseases. Arena's most advanced drug candidate is lorcaserin. Arena's pipeline of compounds targets G protein-coupled receptors.On December 13th, 2021, Arena Pharmaceuticals was acquired by Pfizer at a valuation of $6.7B.

Arena Pharmaceuticals Headquarter Location

6166 Nancy Ridge Drive

San Diego, California, 92121,

United States

858-453-7200

Latest Arena Pharmaceuticals News

SHAREHOLDER ALERT: WeissLaw LLP Reminds APR, ZNGA, BRG, and ARNA Shareholders About Its Ongoing Investigations

Jan 19, 2022

News provided by Share this article If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Apria, Inc. (NASDAQ: APR ) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apria, Inc. (NASDAQ: APR ), in connection with the proposed acquisition of the company by Owens & Minor, Inc. Under the terms of the acquisition agreement, APR shareholders will receive $37.50 in cash for each share of APR common stock that they hold. If you own APR shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/apr Zynga, Inc. (NASDAQ: ZNGA ) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zynga, Inc. (NASDAQ: ZNGA ), in connection with the proposed acquisition of the company by Take-Two Interactive Software, Inc. ("Take-Two"). Under the terms of the merger agreement, ZNGA stockholders will receive $3.50 in cash and $6.36 in shares of Take-Two common stock for each share of ZNGA common stock that they hold. If you own ZNGA shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/znga Bluerock Residential Growth REIT, Inc. (NYSE: BRG ) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bluerock Residential Growth REIT, Inc. (NYSE: BRG ), in connection with the proposed acquisition of BRG by affiliates of Blackstone Real Estate. Under the terms of the merger agreement, BRG shareholders will receive $24.25 in cash for each share of BRG common stock that they hold. Additionally, BRG shareholders will receive shares of the newly formed real estate investment trust named Bluerock Homes Trust, Inc., with a current implied Net Asset Value estimated at $5.60 for each share of BRG common stock. If you own BRG shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/brg   Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ), in connection with the proposed acquisition of the company by Pfizer Inc. Under the terms of the merger agreement, ARNA shareholders will receive $100.00 in cash for each share of ARNA common stock that they hold. If you own ARNA shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/arna    SOURCE WeissLaw LLP

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Arena Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arena Pharmaceuticals is included in 2 Expert Collections, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Arena Pharmaceuticals Patents

Arena Pharmaceuticals has filed 168 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Designer drugs
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/24/2019

1/4/2022

Cannabinoids, Designer drugs, Autoimmune diseases, Rare diseases, Inflammations

Grant

Application Date

9/24/2019

Grant Date

1/4/2022

Title

Related Topics

Cannabinoids, Designer drugs, Autoimmune diseases, Rare diseases, Inflammations

Status

Grant

Arena Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Arena Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.